Amgen announces departure of chief financial officer

Amgen has announced that its executive vice-president and chief financial officer (CFO) Jonathan Peacock is leaving the company.

Mr Peacock stepped down from the CFO role on January 10th 2014 and will remain with the company until May in order to assist with the transition. The search for a permanent successor has already commenced.

Since joining Amgen in 2010, Mr Peacock has played a key role in helping the organisation to expand globally, strengthen its pipeline and deliver improved value for its shareholders.

Michael Kelly, an 11-year Amgen veteran, has been appointed as Amgen's acting CFO, taking responsibility for its finance and investor relations operations on a temporary basis.

Robert Bradway, chairman and chief executive officer at Amgen, said: "Michael Kelly is an experienced financial executive. I am delighted to have him reporting to me as acting CFO while we search for Jon's successor."

This comes after the firm announced the promotion of Brian McNamee and Stuart Tross to new roles within its senior executive team last October.